Leukemia Research
Volume 33, Issue 12 , Pages 1636-1642 , December 2009

Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias

  • Suzanne M. Vercauteren

      Affiliations

    • Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada
    • ,
  • Ali Bashashati

      Affiliations

    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Donghong Wu

      Affiliations

    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Ryan R. Brinkman

      Affiliations

    • Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
    • ,
  • Connie Eaves

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    • Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
    • ,
  • Allen Eaves

      Affiliations

    • Department of Medicine, University of British Columbia, Vancouver, Canada
    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
    • ,
  • Aly Karsan

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
    • Medical Biophysics, British Columbia Cancer Agency, Vancouver, Canada
    • Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada
    • Corresponding Author InformationCorresponding author at: BC Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, Canada V5Z 1L3. Tel.: +1 604 675 8033; fax: +1 604 675 8049.

Received 20 January 2009 ,Revised 6 March 2009 ,Accepted 14 March 2009.

References 

  1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292
  2. Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 2004;6:547
  3. Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood. 2004;103:4285
  4. Nilsson L, Astrand-Grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D, et al. Involvement and functional impairment of the CD34(+)CD38(−)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100:259
  5. Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H. Recent advances in myelodysplastic syndromes. Exp Hematol. 2007;35:137
  6. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73:405
  7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189
  8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835
  9. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079
  10. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118
  11. Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol. 2001;116:177
  12. Oka Y, Kameoka J, Hirabayashi Y, Takahashi R, Ishii T, Sasaki T, et al. Reversible bone marrow dysplasia in patients with systemic lupus erythematosus. Intern Med. 2008;47:737
  13. Mills AE, Meyer JH, Karabus CD, Meyer MP. Transient dyserythropoiesis occurring during the involutionary phase of stage IV-S neuroblastoma. Am J Pediatr Hematol Oncol. 1989;11:23
  14. Laurenti L, Chiusolo P, Garzia MG, Zini G, Sora F, Piccirillo N, et al. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Haematologica. 2002;87:59
  15. Katsarou O, Terpos E, Patsouris E, Peristeris P, Viniou N, Kapsimali V, et al. Myelodysplastic features in patients with long-term HIV infection and haemophilia. Haemophilia. 2001;7:47
  16. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727
  17. Johnson GR. Colony formation in agar by adult bone marrow multipotential hemopoietic cells. J Cell Physiol. 1980;103:371
  18. Eaves CJ, Eaves AC. Erythroid progenitor cell numbers in human marrow—implications for regulation. Exp Hematol. 1979;7(Suppl. 5):54
  19. Geissler K, Hinterberger W, Jager U, Bettelheim P, Neumann E, Haas O, et al. Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. Blut. 1988;57:45
  20. Mayani H, Baines P, Bowen DT, Jacobs A. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia. 1989;3:29
  21. Merchav S, Nagler A, Fleischer-Kurtz G, Tatarsky I. Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. Br J Haematol. 1989;73:158
  22. Carlo-Stella C, Cazzola M, Bergamaschi G, Bernasconi P, Dezza L, Invernizzi R, et al. Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia. 1989;3:363
  23. Stem Cell Technologies Inc., Human Colony-Forming Cell Assays Using Methocult. Stem Cell Technologies Inc. Technical Manual Catalog #28404, 2004.
  24. Coulombel L, Eaves C, Kalousek D, Gupta C, Eaves A. Long-term marrow culture of cells from patients with acute myelogenous leukaemia. Selection in favor of normal phenotypes in some but not all cases. J Clin Invest. 1985;75:961
  25. Ihaka R, Gentleman R. A language for data analysis and graphics. J. Comput. Graph. Stat. 1996;5:299
  26. R Development Core Team RDC. A language and environment for statistical computing. ISBN 3-900051-07-0 URL http://www.R-project.org, 2005.
  27. Breiman L. Random forests. Mach. Learning. 2001;45:5
  28. Nagler A, Binet C, Mackichan ML, Negrin R, Bangs C, Donlon T, et al. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood. 1990;76:1299
  29. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99:1594
  30. Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K. Colony growth characteristics in chronic myelomonocytic leukaemia. Leuk Res. 1988;12:373
  31. Marisavljevic D, Rolovic Z, Sefer D, Basara N, Ilic D, Boskovic D, et al. Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes. Med Oncol. 2002;19:249
  32. Berer A, Jager E, Sagaster V, Streubel B, Wimazal F, Sperr WR, et al. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. Ann Hematol. 2003;82:271
  33. Juvonen E, Aimolahti A, Volin L, Ruutu T. The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. Leuk Res. 1999;23:889
  34. Hamblin T. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res. 1992;16:3
  35. Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol. 2007;67:140
  36. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med. 1992;117:739
  37. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 1995;89:831
  38. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59
  39. Jung YJ, Cha JE, Kim HJ, Ju SY, Cho SJ, Cho KA, et al. Erythropoietin-independent and -dependent stages during in vitro erythropoiesis. Acta Haematol. 2007;118:222
  40. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68
  41. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87:4076
  42. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrom. GM/EPO MDS Study Group. Blood. 2000;95:1175

PII: S0145-2126(09)00142-8

doi: 10.1016/j.leukres.2009.03.019

Leukemia Research
Volume 33, Issue 12 , Pages 1636-1642 , December 2009

Article Tools

* Image Usage & Resolution